| Daehan Nupharm Reports KRW 101.7 Billion in First-Half Sales and KRW 7.3 Billion in Operating Profit... Strengthening R&D-Driven Growth Foundation 2025.08.13 | 
|---|
| Daehan Nupharm recorded KRW 101.7 billion in sales and KRW 7.3 billion in operating profit in the first half of 2025.  R&D investment totaled KRW 6.8 billion, accounting for 6.7% of total sales — a 3% increase year-on-year. This increase reflects the company’s ongoing efforts to strengthen its R&D pipeline and expand research personnel and equipment ahead of its new plant operations. Currently, the Central Research Institute is developing 10 improved drug candidates, while the Biotech Research Institute is conducting research on four new drug candidates. Among them, a veterinary biopharmaceutical product is expected to complete clinical trials this year and launch next year, making it the first to be commercialized. Rather than focusing on short-term profitability, Daehan Nupharm is prioritizing strategic investments to strengthen technological competitiveness and expand its product portfolio. The company is channeling its R&D capabilities to align with the upcoming GMP plant operations and plans to drive growth and increase corporate value through new product launches and global market expansion. 
 Moving forward, Daehan Nupharm will continue to enhance its competitiveness in the pharmaceutical industry by investing in R&D and upgrading production infrastructure, securing a solid momentum for sustainable growth. | 


 Home
 Home